Pancreatic gene variants potentially associated with dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes.

Pharmacogenomics 2014 Feb;15(2):235-49

Department of Pharmacy, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia.

In the adult pancreas, the expression of the genes PAX4, KCNQ1, TCF7L2, KCNJ11, ABCC8, MTNR1B and WFS1 are mainly restricted to β cells to maintain glucose homeostasis. We have identified these genes as the main regulators of incretin-mediated actions, and therefore they may potentially influence the response of DPP-4 inhibitors. This review represents the first detailed exploration of pancreatic β-cell genes and their variant mechanisms, which could potentially affect the response of DPP-4 inhibitors in Type 2 diabetes. We have focused on the signaling pathways of these genes to understand their roles in gastrointestinal incretin-mediated effects; and finally, we sought to associate gene mechanisms with their Type 2 diabetes risk variants to predict the responses of DPP-4 inhibitors for this disease.

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs.13.234DOI Listing
February 2014
26 Reads
1 Citation
3.220 Impact Factor

Publication Analysis

Top Keywords

type diabetes
12
dpp-4 inhibitors
12
response dpp-4
8
exploration pancreatic
4
detailed exploration
4
represents detailed
4
pancreatic β-cell
4
β-cell genes
4
mechanisms affect
4
variant mechanisms
4
genes variant
4
maintain glucose
4
review represents
4
inhibitors review
4
genes main
4
identified genes
4
homeostasis identified
4
main regulators
4
regulators incretin-mediated
4
affect response
4

Similar Publications